HilleVax, Inc. (HLVX)
NASDAQ: HLVX · Real-Time Price · USD
1.900
+0.030 (1.60%)
Nov 4, 2024, 4:00 PM EST - Market closed
Company Description
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States.
It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.
The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021.
HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.
HilleVax, Inc.
| Country | United States |
| Founded | 2020 |
| IPO Date | Apr 29, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 90 |
| CEO | Robert Hershberg |
Contact Details
Address: 321 Harrison Avenue, 5th floor Boston, Massachusetts 02118 United States | |
| Phone | 617 213 5054 |
| Website | hillevax.com |
Stock Details
| Ticker Symbol | HLVX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001888012 |
| CUSIP Number | 43157M102 |
| ISIN Number | US43157M1027 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Robert M. Hershberg M.D., Ph.D. | Co-Founder, President, Chief Executive Officer and Chairman of the Board |
| Dr. Aditya Kohli Ph.D. | Co-Founder, Chief Business Officer and Director |
| Astrid Borkowski M.D., Ph.D. | Chief Medical Officer |
| Shane A. Maltbie | Chief Financial Officer and Treasurer |
| Sean McLoughlin | Chief Operating Officer |
| Dr. Anju Chatterji Ph.D. | Chief Technology Officer |
| Paul S. Bavier J.D. | General Counsel, Secretary and Chief Administrative Officer |
| Ozzie Berger | Senior Vice President of Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 16, 2024 | 8-K | Current Report |
| Aug 9, 2024 | 10-Q | Quarterly Report |
| Aug 9, 2024 | 8-K | Current Report |
| Jul 31, 2024 | 8-K | Current Report |
| Jul 23, 2024 | 8-K | Current Report |
| Jul 22, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Jul 8, 2024 | 8-K | Current Report |
| Jun 10, 2024 | 8-K | Current Report |
| May 31, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| May 9, 2024 | EFFECT | Notice of Effectiveness |